Literature DB >> 15463712

Atovaquone - a novel broad-spectrum anti-infective drug.

A T Hudson1.   

Abstract

Atovoquone is a novel hydroxynaphthoquinone that is currently showing clinical promise for the treatment of malaria and the AIDS-associated diseases Pneumocystis carinii pneumonia and toxoplosmosis. The drug is the end product of half a century of research by numerous groups who have investigated the ontiporositic properties of many related compounds. Atovaquone is the only member of the series to show therapeutic activity in humans when taken orally. In this article, Alan Hudson explores the background to the discovery of this drug and reviews its mode of action, and biological and clinical profiles.

Entities:  

Year:  1993        PMID： 15463712     DOI： 10.1016/0169-4758(93)90040-m

Source DB:  PubMed          Journal:  Parasitol Today        ISSN： 0169-4758


  16 in total

1.  Variations in frequencies of drug resistance in Plasmodium falciparum.

Authors:  P K Rathod; T McErlean; P C Lee
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

Review 2.  Purine and pyrimidine pathways as targets in Plasmodium falciparum.

Authors:  María Belén Cassera; Yong Zhang; Keith Z Hazleton; Vern L Schramm
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

3.  In vitro activity of lumefantrine (benflumetol) against clinical isolates of Plasmodium falciparum in Yaoundé, Cameroon.

Authors:  L K Basco; J Bickii; P Ringwald
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

4.  Frequency of drug resistance in Plasmodium falciparum: a nonsynergistic combination of 5-fluoroorotate and atovaquone suppresses in vitro resistance.

Authors:  S Gassis; P K Rathod
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

5.  Development and characterization of a rapid screening assay for identifying antipneumocystis agents.

Authors:  A Martinez; J A Kovacs
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

6.  4-aminoquinoline analogs of chloroquine with shortened side chains retain activity against chloroquine-resistant Plasmodium falciparum.

Authors:  R G Ridley; W Hofheinz; H Matile; C Jaquet; A Dorn; R Masciadri; S Jolidon; W F Richter; A Guenzi; M A Girometta; H Urwyler; W Huber; S Thaithong; W Peters
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

7.  Antipneumocystis activity of 17C91, a prodrug of atovaquone.

Authors:  J C Comley; C L Yeates; T J Frend
Journal:  Antimicrob Agents Chemother       Date:  1995-10       Impact factor: 5.191

Review 8.  Natural products as starting points for future anti-malarial therapies: going back to our roots?

Authors:  Timothy N C Wells
Journal:  Malar J       Date:  2011-03-15       Impact factor: 2.979

9.  Experimental Chemotherapy for Chagas Disease: A Morphological, Biochemical, and Proteomic Overview of Potential Trypanosoma cruzi Targets of Amidines Derivatives and Naphthoquinones.

Authors:  Solange L de Castro; Denise G J Batista; Marcos M Batista; Wanderson Batista; Anissa Daliry; Elen M de Souza; Rubem F S Menna-Barreto; Gabriel M Oliveira; Kelly Salomão; Cristiane F Silva; Patricia B Silva; Maria de Nazaré C Soeiro
Journal:  Mol Biol Int       Date:  2011-06-30

Review 10.  Malaria in South America: a drug discovery perspective.

Authors:  Luiza R Cruz; Thomas Spangenberg; Marcus V G Lacerda; Timothy N C Wells
Journal:  Malar J       Date:  2013-05-24       Impact factor: 2.979
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.